Bio-Rad further expands molecular portfolio with launch of bulk urine negative and bulk CSF negative matrices
Bio-Rad Laboratories has expanded its molecular offering of quality controls with the launch of two new Exact Diagnostics products: Bulk Urine Negative and Bulk CSF Negative. Both are matrices designed for spike-in or dilution purposes as well as to be used with molecular assays to monitor their intra- and inter-run performance.
These products may also help in the detection of errors in laboratory testing procedures, including potential contamination events.
The Exact Diagnostics Bulk Urine Negative is intended to be validated as an independent external quality run control to monitor the absence of Adenovirus (ADV), BK virus (BKV), Candida auris (C. auris), Chlamydia trachomatis (CT), Cytomegalovirus (CMV), John Cunningham virus (JCV), Mycoplasma genitalium (MG), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Zika virus (ZKV) in various molecular assays.
The Exact Diagnostics Bulk CSF Negative is an independent external quality run control intended to monitor the absence of Anaplasma phagocytophilum, Babesia microti, Bartonella quintana, Borrelia burgdorferi, Ehrlichia chaffeensis, Enterovirus (EV), Herpes Simplex Virus-1 (HSV- 1), Herpes Simplex Virus-2 (HSV-2), and Varicella Zoster Virus (VZV) in various molecular assays.
These two new products are the newest additions to Bio-Rad’s family of negative run controls and matrices in its molecular portfolio, which also includes the Exact Diagnostics Negative Run Control & Exact Diagnostics Bulk Negative (plasma), Exact Diagnostics STI Negative Run Control, Exact Diagnostics Synthetic Negative Run Control and Exact Diagnostics HAI Negative Run Control, the last three having been released late last year.
